scPharmaceuticals Inc. (SCPH)

Market Cap	212.22M
Revenue (ttm)	41.98M
Net Income (ttm)	-90.78M
Shares Out	52.79M
EPS (ttm)	-1.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	180,814
Open	4.000
Previous Close	3.990
Day's Range	3.891 - 4.165
52-Week Range	1.940 - 5.650
Beta	0.36
Analysts	Strong Buy
Price Target	14.00 (+248.26%)
Earnings Date	May 14, 2025

About SCPH

scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care. The company’s lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-de...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 17, 2017
• Employees: 164
• Stock Exchange: NASDAQ
• Ticker Symbol: SCPH
• Website: https://www.scpharmaceuticals.com

Financial Performance

In 2024, scPharmaceuticals's revenue was $36.33 million, an increase of 167.28% compared to the previous year's $13.59 million. Losses were -$85.15 million, 55.4% more than in 2023.

Analyst Forecast

According to 3 analysts, the average rating for SCPH stock is "Strong Buy." The 12-month stock price forecast is $14.0, which is an increase of 248.26% from the latest price.

Price Target

$14.0

(248.26% upside)

Analyst Consensus: Strong Buy